Podium to Practice: Chicago 2025 – Lung: TROPION-Lung02

Podium to Practice: Chicago 2025 – Lung: TROPION-Lung02

Podium to Practice: Chicago 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Barb Melosky

Icon Chair Speaker

Speakers

Dr. Rosalyn Juergens

Dr. Kevin Jao

Studies / Trials Discussed

8501 – TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC).

This program has been made possible through unrestricted support from Boehringer Ingelheim.

Studies/trials discussed:

8501 – TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC).
Tagged